Innate Pharma S.A.
IPHANASDAQHealthcare● Active
$1.76
+$0.05(+2.92%)
Market Cap$165269787
P/E Ratio—
52W High$2.63
52W Low$1.17
Innate Pharma S.A. (IPHA) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IPHA · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($47.24M) | ($49.47M) | ($7.57M) | ($58.10M) | ($52.81M) |
| Depreciation & Amort. | $1.33M | $1.99M | $5.09M | $45.41M | $4.60M |
| Stock-Based Comp. | $0.00M | $3.94M | $4.26M | $4.25M | $2.62M |
| Change in Working Capital | ($10.21M) | $39.16M | ($32.09M) | ($12.50M) | ($9.88M) |
| Net Cash from Operations | ($50.67M) | ($6.90M) | ($32.56M) | ($19.15M) | ($58.46M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.13M) | ($0.39M) | ($2.35M) | ($1.12M) | ($1.33M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $13.51M | $9.59M | $22.77M | $3.00M | $0.00M |
| Net Cash from Investing | $7.00M | $9.20M | $20.63M | $1.88M | ($0.92M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($8.56M) | ($8.94M) | ($2.36M) | ($2.03M) | $26.63M |
| Net Cash from Financing | $5.83M | ($6.01M) | ($1.97M) | ($1.83M) | $26.82M |
| Free Cash Flow | |||||
| Free Cash Flow | ($50.81M) | ($7.29M) | ($34.91M) | ($20.28M) | ($59.79M) |
| FCF Margin %(computed) | — | -57.74% | -67.26% | -35.16% | -493.62% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · EUR · M
Explore more Innate Pharma S.A. data
About Innate Pharma S.A. (IPHA) Cash Flow Statement
Innate Pharma S.A. generated operating cash flow of ($0.05B) and free cash flow of ($0.05B) for 2025 — a FCF margin of -1823.01%. Capital expenditure was ($0.00B).
Frequently asked questions
IPHA · 4 questionsInnate Pharma S.A. generated free cash flow of ($0.05B) for 2025, down 597.2% year-over-year.
IPHA free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10